Results 191 to 200 of about 718,683 (284)

Tumor cell intrinsic dsRNA innate immune response triggered by PARP inhibitor is compromised in BRCA1-deficient breast cancer by repressing IRF3. [PDF]

Protein Cell
Zhang C, Zhou JB, Lei JH, Ang IL, Miao K, Xu X, Poon TCW, Cheung E, Deng CX.   +8 more
europepmc   +1 more source

NRF2/xCT‐Mediated Antioxidant Adaptation Attenuates Apoptosis Induced by ASCT2 Inhibition in Prostate Cancer

Cancer Science, EarlyView.
ASCT2 inhibition induces ROS accumulation and activates NRF2‐dependent xCT upregulation in prostate cancer. This adaptive response partially supports residual cystine acquisition and glutathione synthesis, whereas combined ASCT2 and xCT inhibition disrupts redox compensation and predominantly promotes apoptotic cell death.
Jiaxing Wei, Yasutaka Yamada, Takaaki Tamura, Masahiro Sugiura, Xue Zhao, Meng Ni, Adilan Aierken, Tomokazu Sazuka, Yusuke Imamura, Shinichi Sakamoto   +9 more
wiley   +1 more source

RECQL1 as a potential therapeutic target for PARP inhibitor-resistant ovarian cancer. [PDF]

Sci Rep
Yoshida H, Li J, Inui H, Rokugawa K, Fujiwara K.   +4 more
europepmc   +1 more source

Genetic Evolution in BRCA1‐Associated Breast Cancer Reveals Early Driver Mutations Shaping Tumor Features and Prognosis

Cancer Science, EarlyView.
Multi‐region sequencing of 57 BRCA1‐associated breast cancers identified TP53 as the dominant initial driver, defining a triple‐negative subgroup with biallelic BRCA1 loss and elevated genomic instability. TP53 truncating mutations were enriched in BRCA1 carriers and linked to reduced HRD, EMT activation, and a trend toward worse survival.
Li Hu, Zhongwu Li, Qiting Wan, Xingyu Liao, Yaxin Zhang, Qian Liu, Xinyun Ding, Hua Meng, Yifan Wu, Jie Sun, Juan Zhang, Lu Yao, Ye Xu, Yuntao Xie   +13 more
wiley   +1 more source

PARP1-BCAT2 axis upregulates ABCG1 via histone lactylation to drive acquired PARP inhibitor resistance in prostate cancer. [PDF]

J Exp Clin Cancer Res
Mei W, Zhou H, Li W, Liu Y, Tang C, Wei M, Zhou Z, Ye B, Niu H, Wang W, Yang K, Zhang Y, Huang L, Yu Y, Wen X, Ye L.   +15 more
europepmc   +1 more source

Selective Depletion of Tumor‐Infiltrating CD4+CCR8+ Tregs by AZ084, a Novel CCR8 Antagonist

Cancer Science, EarlyView.
AZ084, a novel CCR8 antagonist, selectively targets tumor‐infiltrating CD4+CCR8+ Tregs, reduces their immunosuppressive function, and decreases IL‐10/TGF‐β production. ABSTRACT Regulatory T cells (Tregs) are key mediators of immunosuppression in ovarian cancer, yet strategies for selectively targeting tumor‐infiltrating Tregs remain limited.
Yepeng Mao, Ziqi Tao, Shuna Liu, Zhijie Liu, Yuelu Zhang, Lingfei Zhou, Lina Yan, Ting Wang, Wenwen Shang, Jianfang Lou, Xi Huang, Xin Fu, Fang Wang   +12 more
wiley   +1 more source

Enhancing PARP inhibitor efficacy in ovarian cancer: targeting the PI3K/AKT/mTOR pathway. [PDF]

J Ovarian Res
Wang Y, Xia Q, Wang X, Lu Y, Wang S, Jiao Y.   +5 more
europepmc   +1 more source

New Treatment Strategy and Future Research Direction for BRAF‐Mutated Cancer

Cancer Science, EarlyView.
Treatment with BRAF inhibitor plus MEK inhibitor is currently used in BRAF‐mutated various malignancies except colorectal cancer, and treatments with BRAF and/or MEK inhibitors and anti‐EGFR antibody are used in BRAF‐mutated colorectal cancer. Despite recent advances in BRAF‐targeted therapies, their efficacy is still limited.
Masanobu Takahashi, Sakura Hiraide Taniguchi, Yuya Yoshida   +2 more
wiley   +1 more source

Targeting IP₆ signaling to destabilize homologous recombination proteins to overcome PARP inhibitor resistance. [PDF]

Nat Commun
Lee SG, Seo Y, Jeong S, Chung Y, Kong S, Kim M, Rhlee JH, Um S, Mathew BP, Maiti S, Kuram MR, Abozeid MA, Park A, Yoo JN, Khim KW, Son K, Amarsanaa E, Kim K, Hong S, Choi J, Park IB, Lee EA, Jeon JH, Park JH, Han JS, Park CY, Kim S, Choi JH, Hong SY, Seo MD, Lee H, Lee JY, Myung K.   +32 more
europepmc   +1 more source

The PRIME trial: An investigator‐initiated, multicentre, phase II study of the poly(ADP‐ribose) polymerase inhibitor olaparib in isocitrate dehydrogenase (IDH)‐mutated relapsed/refractory acute myeloid leukaemia and myelodysplastic syndromes

British Journal of Haematology, EarlyView.
Rory M. Shallis, Jennifer VanOudenhove, Namrata Chandhok, Justin Watts, Deepa Jeyakumar, Daniel R. Reed, Jan Phillip Bewersdorf, Diane Durecki, Scott Boerner, Richard F. Little, Steven D. Gore, Jing Li, Xun Bao, Li Chen, Sayak Ghatak, Thomas Prebet, Ranjit S. Bindra, Amer M. Zeidan, Stephanie Halene   +18 more
wiley   +1 more source